FindTrial
Sign In

Efficacy of memantine in patients with moderate-to-severe Alzheimer's disease: results of pooled analysis, using realistic definitions of response, of two randomized, double-blind, placebo-controlled trials in Japan

Efficacy of memantine in patients with moderate-to-severe Alzheimer's disease: results of pooled analysis, using realistic definitions of response, of two randomized, double-blind, placebo-controlled trials in Japan - A pooled analysis of efficacy of memantine in patients with moderate-to-severe Alzheimer's disease (MEM-DS-15019)

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000026013
Enrollment
633
Registered
2017-02-06
Start date
2017-02-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer&#39

Interventions

None listed

Sponsors

Daiichi Sankyo Co., LTD.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with moderate to severe AD who participated in a late phase II study and a phase III study, and were treated with either memantine at 20 mg/day or placebo.

Exclusion criteria

Exclusion criteria: Patients who did not have a result of efficacy assessment at the start of the study

Design outcomes

Primary

MeasureTime frame
Proportion of patients showing clinical worsening in individual domains, and in combined multiple domains. Domains are as follows: - SIB-J (cognition) - CIBIC plus-J (Global ststus) - FAST (Function) - Behave-AD (BPSD)—

Countries

Japan

Contacts

Public ContactDaiju Matsui

Daiichi Sankyo Co., LTD. Oncology & Pain Group, Medical Science Department

matsui.daiju.ks@daiichisankyo.co.jp03-6225-1046

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026